Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of tisotumab vedotin versus investigator's choice chemotherapy in recurrent or metastatic cervical cancer
NL-OMON51118Phase 3Recruiting
- Sponsor
- Seagen Inc.
- Start
- Dec 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tisotumab vedotin, sponsored by Seagen Inc. Started Dec 2021; status: recruiting.
02
Drugs
tisotumab vedotin
Beyond the preview
Go deeper on NL-OMON51118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51118.